Vigil Neuroscience (NASDAQ:VIGL) Trading Up 0.4% - Here's What Happened

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) shares were up 0.4% on Tuesday . The company traded as high as $8.03 and last traded at $8.02. Approximately 580,307 shares were traded during trading, a decline of 15% from the average daily volume of 683,086 shares. The stock had previously closed at $7.99.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on VIGL shares. Jefferies Financial Group lowered shares of Vigil Neuroscience to a "hold" rating in a report on Thursday, May 22nd. JMP Securities restated a "market perform" rating on shares of Vigil Neuroscience in a research report on Thursday, May 22nd. William Blair downgraded shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Stifel Nicolaus downgraded shares of Vigil Neuroscience from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $11.00 to $8.00 in a research report on Wednesday, May 28th. Finally, HC Wainwright downgraded shares of Vigil Neuroscience from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $14.00 to $8.00 in a research report on Tuesday, May 27th. Ten investment analysts have rated the stock with a hold rating, According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $10.80.

Vigil Neuroscience Trading Up 0.1%

The firm's 50-day moving average is $6.29 and its two-hundred day moving average is $3.51. The stock has a market cap of $382.24 million, a price-to-earnings ratio of -3.91 and a beta of 3.34.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.04. On average, analysts predict that Vigil Neuroscience, Inc. will post -2.07 earnings per share for the current year.

Institutional Trading of Vigil Neuroscience

Large investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC grew its stake in shares of Vigil Neuroscience by 53.0% in the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after buying an additional 8,358 shares during the period. Jane Street Group LLC purchased a new stake in shares of Vigil Neuroscience in the 4th quarter valued at approximately $83,000. Barclays PLC grew its stake in shares of Vigil Neuroscience by 43.6% in the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after buying an additional 19,436 shares during the period. Northern Trust Corp grew its stake in shares of Vigil Neuroscience by 29.0% in the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after buying an additional 14,572 shares during the period. Finally, Two Sigma Advisers LP grew its stake in shares of Vigil Neuroscience by 243.8% in the 4th quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock valued at $117,000 after buying an additional 49,000 shares during the period. Hedge funds and other institutional investors own 83.64% of the company's stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.